Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 7


Will Open Government make Canada's health agencies more transparent?

H├ębert PC, Coutts J, Stanbrook MB, MacDonald N, Flegel K.

CMAJ. 2011 Apr 5;183(6):641-2. doi: 10.1503/cmaj.110411. Epub 2011 Mar 21. No abstract available.


The new oral anticoagulants.

Garcia D, Libby E, Crowther MA.

Blood. 2010 Jan 7;115(1):15-20. doi: 10.1182/blood-2009-09-241851. Epub 2009 Oct 30. Review.


Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.

Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM.

CMAJ. 2008 Aug 26;179(5):438-46. doi: 10.1503/cmaj.071540.


Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.


Progressive drug licensing: an opportunity to achieve transparency and accountability?

Wright JM.

CMAJ. 2007 Jun 19;176(13):1848-9. No abstract available.


Health Canada's Progressive Licensing Framework.

Yeates N, Lee DK, Maher M.

CMAJ. 2007 Jun 19;176(13):1845-7. No abstract available.


Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk